Clinical trial · Observational
A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors
A Prospective, Multicenter, Non-interventional Registry Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Malignant Solid Tumors in Sichuan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were selected from the first chemotherapy cycle using PEG-rhG-CSF (can be any chemotherapy cycle of the patient), and each subsequent chemotherapy cycle was recorded. The use of PEG-rhG-CSF and related patient outcomes until the end of chemotherapy. Analyze the clinical practice of using PEG-rhG-CSF in the real world.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neutropenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pegfilgrastim（PEG-rhG-CSF） | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Dosage of PEG-rhG-CSF in chemotherapy
- timeFrame
- 1 YEAR
- measure
- Administration time of PEG-rhG-CSF in chemotherapy
- timeFrame
- 1 YEAR
- measure
- dosing frequency of PEG-rhG-CSF in chemotherapy
- timeFrame
- 1 YEAR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old; 2. Diagnosed as a malignant solid tumor by histology and cytology, requiring chemotherapy patients; 3. The first use of PEG-rhG-CSF during the chemotherapy cycle (not limited to the first chemotherapy cycle, can be any chemotherapy cycle of the patient); 4. Subjects volunteered to participate in this clinical trial and signed informed consent. Exclusion Criteria: 1. PEG-rhG-CSF was used in the current chemotherapy cycle; 2. Have received hematopoietic stem cell transplantation or bone marrow transplantation; 3. Other drug clinical trials are currently underway.
References
Publications (0)
Data not yet available